Sensitization and Desensitization in Vascularized Composite Allotransplantation

Area of Science:

• Transplantation immunology
• Regenerative medicine
• Surgical reconstruction

Background:

• Vascularized composite allotransplantation (VCA) offers a solution for severe disfiguring defects.
• Lifelong immunosuppression and immune responses pose significant risks in VCA.
• Alloantibody development, particularly anti-HLA antibodies, is a concern following VCA.

Purpose of the Study:

• To explore the role of antibody-mediated rejection (AMR) in VCA.
• To understand the impact of donor-specific antibodies (DSA) on VCA outcomes.
• To review current strategies for managing AMR in VCA recipients.

Main Methods:

• Review of existing literature on VCA and immune rejection.
• Analysis of mechanisms underlying alloantibody-mediated damage.
• Examination of desensitization and treatment protocols for AMR.

Main Results:

• Preexisting and de novo donor-specific antibodies (DSA) are key contributors to late allograft injury and graft failure in VCA.
• Alloantibody-mediated damage involves complement fixation and antibody-dependent cellular toxicity, potentially leading to vascular thrombosis.
• Current desensitization protocols focus on alloantibody removal, with IVIg for established AMR, but long-term efficacy in sensitized VCA recipients is unknown.

Conclusions:

• The understanding of antibody-mediated rejection and DSA in VCA remains incomplete.
• Further research is needed to establish effective long-term therapies for sensitized VCA recipients.
• VCA transplantation is being performed in HLA-sensitized patients, highlighting the need for better management strategies.